#CGTEA2026 | Solution Providers

Powering Innovation in Cell & Gene Therapy Across East Asia

Cell & Gene Therapy East Asia 2026 (#CGTEA2026) will once again bring together the brightest minds and industry leaders from South Korea, Japan, China, and Taiwan to explore the latest breakthroughs in regenerative medicine. As the region accelerates innovation in gene editing, cell therapy, and personalised medicine, #CGTEA2026 will serve as a critical hub for fostering collaboration between biopharma companies, academic and research institutions, and CDMOs.

This year’s conference will focus on cutting-edge advancements in gene-modified cell therapies, scalable manufacturing for next-generation therapeutics, regulatory frameworks shaping the East Asian market, and strategies to drive commercial success in cell and gene therapy. With an emphasis on bridging research with clinical and commercial applications, the event will provide unparalleled insights into the future of precision medicine.

Under the umbrella of Biologics World Korea 2026 (#BWK2026), #CGTEA2026 will be co-located with Biologics Manufacturing Korea 2026 (#BMK2026) and ADC & Bioconjugate East Asia 2026 (#ADCBio2026), creating a dynamic cross-disciplinary platform for networking, knowledge-sharing, and business growth. Whether you're looking to gain regulatory insights, explore investment opportunities, or forge strategic partnerships, this is the premier event to connect with East Asia’s key players in the cell and gene therapy landscape.